A novel small molecule that inhibits glutaminase isoforms not commonly expressed in normal cells [29] is under study in two phase II trials (NCT03163667 and NCT03428217) for advanced renal cell carcinoma. Here, GLS is linked to hereditary clear cell renal cell carcinoma.